PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2015 | 5 | 3 | A109-116
Article title

Patient with metastatic renal cell carcinoma treated successfully with pazopanib for four years.

Content
Title variants
Languages of publication
EN
Abstracts
EN
We present a case of a patient with metastatic renal cell carcinoma who was treated with pazopanib in the first-line treatment. Although nephrectomy was not performed, there was a positive reaction to the therapy with multi-targeted tyrosine kinase inhibitor. After 18 months of the palliative treatment, the cancerous kidney was surgically removed and pazopanib was restarted with the effect of further disease remission. The development of hypertension, complete hair discoloration and isolated hyperbilirubinemia occurred, and there was occasionally hypokalaemia in laboratory findings within 48 months of therapy. No serious adverse events were reported.
Discipline
Publisher

Journal
Year
Volume
5
Issue
3
Pages
A109-116
Physical description
Contributors
  • Clinical Department of Oncology at the University Hospital in Krak ow, Poland, agnesnew@wp.pl
author
  • Clinical Department of Oncology at the University Hospital in Krak ow, Poland
author
  • Department of Diagnostic Imaging at the University Hospital in Krak ow, Poland
  • Clinical Department of Oncology at the University Hospital in Krak ow, Poland
References
  • 1. Wojciechowska U, Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce w 2010 roku. Warszawa 2012.
  • 2. Srinivasan R, Rosner IL, Linehan WM. Renal cell carcinoma. In: Abraham J, Gulley JL, Allegra CJ et al. The Bethesda Handbook of Clinical Oncology. Lippincott Williams&Wilkins, Philadelphia 2010: 177-178.
  • 3. Escudier B, Bellmunt J, Négrier S et al. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. J Clin Oncol 2010; 28: 2144-2150.
  • 4. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
  • 5. Sun M, Shariat SF, Trinh QD et al. An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. Ther Adv Urol 2013; 5: 121-8.
  • 6. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757–63.
  • 7. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449–56.
  • 8. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256–65.
  • 9. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011; 378: 1931–39.
  • 10. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2010; 28: 1061-8.
  • 11. Kilonzo M, Hislop J, Elders A et al. Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics 2013; 31: 15-24.
  • 12. Sternberg CN, Hawkins RE, Wagstaff J et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. Eur J Cancer 2013; 49: 1287-96.
  • 13. Nieto M, Borregaard J, Ersbøll J et al. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Clin Cancer Res 2011; 17: 6608-14.
  • 14. Motzer RJ, Huston TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722-31.
  • 15. Motzer J, Mazumdar M, Bacik J et al. Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma. J Clin Oncol 1999; 17: 2530-2540.
  • 16. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-841.
  • 17. Seidel C, Busch J, Weikert S et al. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur J Cancer 2012; 48: 1023-30.
  • 18. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655–1659.
  • 19. Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966–970.
  • 20. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 1071–1076.
  • 21. Kwitkowski VE, Prowell TM, Ibrahim A et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010; 15: 428–435.
  • 22. Richey SL, Culp SH, Jonasch E et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 2011; 22: 1048-53.
  • 23. Bex A, Haanen J. Do targeted agents offer clinical benefit as presurgical therapy? World J Urol 2014; 32: 3-8.
  • 24. Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 2009; 115: 2355–2360.
  • 25. Bex A, van der Veldt AA, Blank C et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 2009; 27: 553-9.
  • 26. Aben KK, Heskamp S, Janssen-Heijnen ML et al. Better survival in patients with metastasized kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur J Cancer 2011; 47: 2023–2032.
  • 27. O’Malley RL, Brewer KA, Hayn MH et al. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease-related factors responsible? Urology 2011; 78: 595–600.
  • 28. Choueiri TK, Xie W, Kollmannsberger C et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011; 185: 60–66.
  • 29. Escudier B, Porta C, Bono P et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014; 32: 1412-8.
  • 30. Karam JA, Wood CG. Words of wisdom: re: prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Eur Urol 2013; 63: 769.
  • 31. Tran HT, Liu Y, Zurita AJ et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012; 13: 827-37.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-0f014cef-1d4b-448f-abd5-04cd7b0ca1fe
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.